Filter News
Area of Research
- (-) Nuclear Science and Technology (5)
- Advanced Manufacturing (1)
- Biological Systems (1)
- Biology and Environment (36)
- Clean Energy (146)
- Climate and Environmental Systems (1)
- Computational Biology (2)
- Computational Engineering (2)
- Computer Science (9)
- Electricity and Smart Grid (3)
- Energy Sciences (1)
- Functional Materials for Energy (2)
- Fusion and Fission (8)
- Isotopes (7)
- Materials (53)
- Materials for Computing (7)
- National Security (21)
- Neutron Science (25)
- Quantum information Science (1)
- Sensors and Controls (1)
- Supercomputing (58)
- Transportation Systems (2)
News Type
News Topics
- (-) Biomedical (2)
- (-) Transformational Challenge Reactor (3)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (11)
- Bioenergy (1)
- Computer Science (2)
- Coronavirus (1)
- Cybersecurity (1)
- Decarbonization (1)
- Environment (1)
- Fusion (8)
- Isotopes (5)
- Materials Science (3)
- Molten Salt (4)
- Neutron Science (5)
- Nuclear Energy (36)
- Physics (2)
- Space Exploration (5)
- Sustainable Energy (1)
Media Contacts
It’s a new type of nuclear reactor core. And the materials that will make it up are novel — products of Oak Ridge National Laboratory’s advanced materials and manufacturing technologies.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.
Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.